Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Lee, Seyoung ^a   Evans, Megan A ^a   Chu, Hannah X ^a   Kim, Hyun Ah ^a   Widdop, Robert E ^a   Drummond, Grant R ^a   Sobey, Christopher G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; G PROTEIN COUPLED RECEPTOR; GLUCOSE; NEUROPROTECTIVE AGENT; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1;

ANIMAL CELL; ARTICLE; BRAIN BLOOD FLOW; BRAIN CELL; BRAIN INFARCTION; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; EDEMA; EMBRYO; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; AGONISTS; ANIMAL; BRAIN; C57BL MOUSE; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; NERVE CELL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL DEATH; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; STROKE;

EID: 84951310904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142087     Document Type: Article

References (35)

1. Jauch EC, Saver JL, Adams HP Jr., Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3):870-947. doi: 10. 1161/STR.0b013e318284056a PMID: 23370205
2. Lee S, Brait VH, Arumugam TV, Evans MA, Kim HA, Widdop RE, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012; 4(1):16. doi: 10.1186/2040-7378-4-16 PMID: 22920387
3. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009; 40(4):1482-9. doi: 10.1161/STROKEAHA. 108.531509 PMID: 19246705
4. McCarthy CA, Vinh A, Broughton BR, Sobey CG, Callaway JK, Widdop RE. Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension. 2012; 60 (6):1531-7. doi: 10.1161/HYPERTENSIONAHA.112.199646 PMID: 23090772
5. McCarthy CA, Vinh A, Miller AA, Hallberg A, Alterman M, Callaway JK, et al. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One. 2014; 9(4):e95762. doi: 10.1371/journal.pone.0095762 PMID: 24752645
6. Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodriguez V, Desland F, et al. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology. 2014; 81:134-41. doi: 10.1016/j.neuropharm.2014.01.044 PMID: 24508710
7. Alhusban A, Fouda AY, Bindu P, Ishrat T, Soliman S, Fagan SC. Compound 21 is pro-Angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens. 2015; 33(1):170-80. doi: 10. 1097/HJH.0000000000000364 PMID: 25304472
8. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003; 100 (14):8258-63. PMID: 12829792
9. Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett. 1995; 357(1):27-32. PMID: 8001672
10. Passos-Silva DG, Verano-Braga T, Santos RA. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond). 2013; 124(7):443-56.
11. Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem. 2008; 107(6):1482-94. doi: 10.1111/j.1471-4159.2008.05723.x PMID: 19014390
12. Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol. 2011; 300(4):R804-17. doi: 10.1152/ajpregu.00222.2010 PMID: 21178125
13. Zhang Y, Lu J, Shi J, Lin X, Dong J, Zhang S, et al. Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats. NEuropeptides. 2008; 42(5-6):593-600. doi: 10.1016/j. npep.2008.09.005 PMID: 18990443
14. Mecca AP, Regenhardt RW, O'Connor TE, Joseph JP, Raizada MK, Katovich MJ, et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011; 96(10):1084-96 doi: 10.1113/expphysiol.2011.058578 PMID: 21685445
15. Regenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, Mocco J, et al. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology. 2013; 71:154-63. doi: 10.1016/j. neuropharm.2013.03.025 PMID: 23583926
16. Jiang T, Yu JT, Zhu XC, Zhang QQ, Tan MS, Cao L, et al. Angiotensin-(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas/eNOS-dependent pathway. Br J Pharmacol. 2014; 171(18):4222-32. doi: 10.1111/bph.12770 PMID: 24824997
17. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002; 40(6):847-52. PMID: 12468568
18. Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004; 44(4):490-6. PMID: 15326087
19. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010; 30 (8):1606-13. doi: 10.1161/ATVBAHA.110.204453 PMID: 20448208
20. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond). 2011; 121(7):297-303.
21. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol. 2009; 156(4):680-8. doi: 10.1111/j.1476-5381.2008.00073.x PMID: 19175604
22. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17 (3):472-6. PMID: 3715945
23. Zhao Y, Gu JH, Dai CL, Liu Q, Iqbal K, Liu F, et al. Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice. Front Aging Neurosci. 2014; 6:10. doi: 10.3389/fnagi.2014.00010 PMID: 24575038
24. Heckman LD, Chahrour MH, Zoghbi HY. Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice. eLife. 2014; 3.
25. Jew CP, Wu CS, Sun H, Zhu J, Huang JY, Yu D, et al. mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotion. PLoS One. 2013; 8(8):e70415. doi: 10.1371/journal.pone. 0070415 PMID: 23940572
26. Switonski PM, Szlachcic WJ, Krzyzosiak WJ, Figiel M. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Neurobiol Dis. 2015; 73:174-88. doi: 10.1016/j.nbd.2014.09.020 PMID: 25301414
27. Kamens HM, Phillips TJ, Holstein SE, Crabbe JC. Characterization of the parallel rod floor apparatus to test motor incoordination in mice. Genes, brain, and behavior. 2005; 4(4):253-66. PMID: 15924557
28. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK. ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol. 2006; 91(1-2):163-98. PMID: 16009403
29. Calo LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, et al. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. Journal of nephrology. 2010; 23(4):472-7. PMID: 20349406
30. Jiang T, Gao L, Guo J, Lu J, Wang Y, Zhang Y. Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia. Br J Pharmacol. 2012; 167(7):1520-32. doi: 10.1111/j.1476-5381.2012.02105.x PMID: 22817481
31. Lu J, Jiang T, Wu L, Gao L, Wang Y, Zhou F, et al. The expression of angiotensin-converting enzyme 2-Angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. NEuropeptides. 2013; 47(5):289-95. doi: 10.1016/j.npep.2013.09.002 PMID: 24090950
32. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010; 56(1):112-20. doi: 10.1161/HYPERTENSIONAHA.110.152942 PMID: 20479330
33. Iwata M, Cowling RT, Yeo SJ, Greenberg B. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol. 2011; 51(4):542-7. doi: 10.1016/j.yjmcc.2010.12.003 PMID: 21147120
34. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol. 2010; 185(9):5569-76. doi: 10.4049/jimmunol.1000314 PMID: 20935211
35. Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, et al. Renoprotective effects of AVE0991, a nonpeptide Mas receptor agonist, in experimental acute renal injury. Int J Hypertens. 2012; 2012:808726. doi: 10.1155/2012/808726 PMID: 22319645